ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / OFIX / insiders
EMBC (68) MOBI (50) SI (44) CLPT (19) ⌘ Pro Terminal →

Orthofix Medical Inc. (OFIX) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$8.75 -3.53% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $8.68

Orthofix Medical Inc. (OFIX) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • SELL / AVOID Cap $369.4M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on OFIX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is OFIX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Orthofix Medical Inc. (NASDAQ: OFIX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $8.75 (-3.53% 1D, market cap $369.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 11/20. Across 1016 tracked Health Care issuers, OFIX ranks #425 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does OFIX compare to EMBC and MOBI in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), OFIX carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of 68.8%, and ROIC of -12.2%. By comparison, EMBC (Embecta Corp.) holds a C+ grade (68/100 RQD, P/E 3.9x, ROIC 35.5%, cap $354.1M) and MOBI (Mobia Medical Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC —, cap $352.2M). Among the 5-stock peer group, EMBC leads on earnings multiple (3.9x) while EMBC leads on capital efficiency (35.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for OFIX?
▼

Per OFIX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000884624), Orthofix Medical Inc. generated $822.3M in revenue (+2.9% YoY), -$92.2M in net income, and $33.3M in free cash flow against $850.6M in total assets and $157.4M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $8.68 (-0.83%)🧬 Cannibal Buyback (-0.96% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 4.1% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D-
025507510042
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Cash (8)Whales (4)SEC (10)Macro (9)CEO (11)
Each axis scored 0–20
12M PRICE TARGET CONE-7.2% Base Target
$18 Bull$8 Base$6 Bear
📬 FREE OFIX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for OFIX)Realized 20D OHLCV Swing Band: ±9.5%
Deterministic 5-Pillar Attribution (42/100 Composite)
🔍 WHY OFIX SCORES 42/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Insider Conviction & Share Dilution+11/20 pts (26% of score)

SEC Form 4 / 13F Thermometer: 55% Net Buy • Cannibal Buyback (-0.96% YoY Shares)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (24% of score)

Altman Z-Score 1.02 (DISTRESS RISK (<1.8)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
50
Grade C-$9.26+6.4% Next Q
Q2 (-2Q)
47
Grade D$9.85-1.4% Next Q
Q3 (-1Q)
45
Grade D$9.71-9.9% Next Q
Current
42
Grade D-$8.75-7% Hist 90D α
Trajectory: C- (50) → D- (42)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a OFIX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While OFIX currently carries a cautious 42/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($9.38) and Max Pain ($9.19) forces dealer call-delta covering toward $17.84.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Cannibal Buyback (-0.96% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $OFIX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “OFIX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 42%NO 58%Trade / Inspect Odds →
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

OFIX Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales →
▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (OFIX)

No recent open-market Form 4 cluster sales or emergency dumps flagged on OFIX. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring OFIX)

  • ✓Walkthrough of OFIX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
OFIX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -27.14%▼ DESCENDING CHANNEL
2026-11-03O $10.24H $10.24L $8.75C $8.75VOL 657.9K
RES: $10.56SUP: $8.32SMA50: $9.38SMA200: $11.05
$14.29$12.72$11.15$9.58$8.01RES $10.56SUP $8.32$8.752026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

OFIX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 OFIX Butterfly Map → + Track OFIX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +2.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on OFIX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for OFIX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for OFIX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OFIX)

Health Care Rank #425 of 1016 ⚔️ EMBC vs OFIX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (OFIX vs. EMBC, MOBI, SI, CLPT)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Orthofix Medical Inc. (OFIX) ranks #425 by composite RQD confidence (42/100, grade D-) and #487 by equity capitalization ($369.4M). Within this direct 5-issuer industry benchmark cohort, EMBC leads on earnings valuation at 3.9x trailing P/E, while EMBC leads on capital efficiency and profitability with 35.5% ROIC and 62.6% gross margin. EMBC currently holds the highest overall quantitative score in the immediate peer group at 68/100 (C+) compared with OFIX at 42/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
OFIX ACTIVE
Orthofix Medical Inc.
D- 42/100 — 68.8% -12.2% -3.53% $369.4M Benchmark Subject
EMBC
Embecta Corp.
C+ 68/100 3.9x 62.6% 35.5% -0.96% $354.1M /embc-vs-ofix →
MOBI
Mobia Medical Inc.
D 50/100 — — — -4.82% $352.2M /mobi-vs-ofix →
SI
Shoulder Innovations Inc.
D 44/100 — 76.5% -16.1% +0.99% $398.3M /si-vs-ofix →
CLPT
ClearPoint Neuro Inc.
E 19/100 — 61.4% -35.0% -6.75% $342.0M /clpt-vs-ofix →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000884624

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Orthofix Medical Inc. (OFIX) reported GAAP revenue of $822.3M (+2.9% vs. FY2024 revenue of $799.5M , and +10.1% cumulative change since FY2023) , GAAP net income of -$92.2M, operating cash flow of $33.3M, and free cash flow of $33.3M (+29.3% YoY). On the balance sheet, OFIX closed FY2025 with $850.6M in total assets against $157.4M in total debt (Altman Z-Score: 1.02, Piotroski F-Score: 7/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $822.3M -$92.2M $33.3M $33.3M $850.6M $157.4M
FY2024 (FY) 2024-12-31 $799.5M -$126.0M $25.8M $25.8M $893.3M $157.0M
FY2023 (FY) 2023-12-31 $746.6M -$151.4M -$45.8M -$45.8M — —

3. OFIX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is OFIX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Orthofix Medical Inc. (NASDAQ: OFIX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $8.75 (-3.53% 1D, market cap $369.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 11/20. Across 1016 tracked Health Care issuers, OFIX ranks #425 in composite RQD confidence.

How does OFIX compare to EMBC and MOBI in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), OFIX carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of 68.8%, and ROIC of -12.2%. By comparison, EMBC (Embecta Corp.) holds a C+ grade (68/100 RQD, P/E 3.9x, ROIC 35.5%, cap $354.1M) and MOBI (Mobia Medical Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC —, cap $352.2M). Among the 5-stock peer group, EMBC leads on earnings multiple (3.9x) while EMBC leads on capital efficiency (35.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for OFIX?

Per OFIX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000884624), Orthofix Medical Inc. generated $822.3M in revenue (+2.9% YoY), -$92.2M in net income, and $33.3M in free cash flow against $850.6M in total assets and $157.4M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is OFIX trading relative to its 50-day, 200-day, and 52-week technical levels?

OFIX last traded at $8.75 (-3.53% on volume of 565,630 shares), positioning the stock -6.72% below its 50-day simple moving average ($9.38) and -20.81% below its 200-day simple moving average ($11.05). Across its 52-week range of $8.50 to $16.99, OFIX sits at the 2.9% percentile with a 14-day RSI of 44.8 (NEUTRAL RANGE) and an implied next-earnings move of ±9.5% ($7.92 to $9.58).

Direct Sub-Reports: OFIX RQD Cockpit OFIX 12M Forecast OFIX Earnings & Move OFIX Dividends & DRIP OFIX Insiders & 13F OFIX Whale Options OFIX Profit Sankey OFIX News & Why
ROARABLE RATING BRIEF • RQD 42/100 (D-) ✓ SEC XBRL & RQD VERIFIED

OFIX — Orthofix Medical Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Orthofix Medical Inc. (OFIX) earns a live Roarable RQD composite score of 42/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $8.75 (-3.53% 1D, market capitalization $369.4M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -12.2%, gross margin of 68.8%, operating margin of -9.9%, and free cash flow yield of 7.99%.
  • Whale 13F & Options Flow (4/20) + Insider Conviction (10/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (11/20): Incorporates a 1.00x equity beta, Altman Z-Score of 1.02, Piotroski F-Score of 7/9, and Debt/Equity of 0.35x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Orthofix Medical Inc. (OFIX) is a NASDAQ-listed issuer in the Health Care sector, operating within the Medical/Dental Instruments industry (per the company profile). Per the market data, gross margin is 68.8%, which indicates the product mix carries high gross profitability.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Orthofix Medical Inc. (OFIX) reported $822.3M in annual revenue (up from $799.5M in FY2024, +2.9% YoY) and -$92.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($746.6M revenue, -$151.4M net income) through FY2025, OFIX scaled operating cash flow to $33.3M and free cash flow to $33.3M, backed by $850.6M in total assets against $157.4M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 42/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of 7.99% and institutional whale pillar of 4/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $8.50 – $16.99 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh current valuation against -9.9% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream suppliers, downstream customers, and sector correlations beyond the Health Care / Medical-Dental Instruments classification are not provided.

  • Key Question #1: Can OFIX sustain or expand its -9.9% operating margin and -12.2% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $822.3M and free cash flow of $33.3M, how will capital allocation balance growth reinvestment against $157.4M in total debt?
  • Key Question #3: How sensitive is OFIX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

OFIX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Orthofix Medical Inc. (OFIX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to OFIX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

OFIX Bull vs. Bear Conversation Board — What's Your Call at $8.75?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON OFIX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on OFIX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $11.25 (+24.0%)
📌 Pinned Debate

Revenue rose from $746.6M to $822.3M across FY 2023–FY 2025 while the operating loss narrowed from -$139.1M to -$81.4M, and the 68.8% g

Here is why I am bullish on OFIX here at $9.07: Revenue rose from $746.6M to $822.3M across FY 2023–FY 2025 while the operating loss narrowed from -$139.1M to -$81.4M, and the 68.8% gross margin and 7.99% FCF yield are supportive.. Compare OFIX's -9.9% operating margin and -12.2% ROIC against the rest of Medical/Dental Instruments. As long as cash conversion holds up, dips toward $8.62 are getting bought.

CapAlloc_Nerd 🐂 BULL

@MultipleCompression Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Medical/Dental Instruments. If gross margin (68.8%) holds, EPS grows into the multiple faster than bears think.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $6.98 (-23.0%)
Spot @ $9.07

ROIC of -12.2%, an Altman Z-Score of 1.02, and an RQD score of 47 (D) with a distribution-warning verdict point to weak fundamentals an

ROIC of -12.2%, an Altman Z-Score of 1.02, and an RQD score of 47 (D) with a distribution-warning verdict point to weak fundamentals and elevated risk.. Look at the math on OFIX: paying current EV/EBITDA multiples for -12.2% ROIC and -9.9% operating margins leaves zero margin of safety if Medical/Dental Instruments demand softens. I'd wait for a retest of $7.98 before getting long.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%